Project Grant R01HL179125
Award Date 8/1/26
Completion Date 4/30/28
Dollars Obligated $1.4M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90095, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded New York University $836,736 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial mechanosensing of circulatory flow in health and disease. The project will examine how endothelial cells lining blood and lymphatic vessels respond to fluid flow forces, with focus on the roles of PLXND1 (a transmembrane semaphorin receptor) and KLF2 (a transcription factor) in endothelial responses to...
- The National Heart, Lung, and Blood Institute awarded University of California, Los Angeles $118,125 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of collagen type VIII in atherosclerotic plaque vulnerability. The research examines how collagen VIII, particularly its COL8A1 component, influences atherosclerotic plaque stability through its effects on smooth muscle cell recruitment and endothelial-to-mesenchymal transition. Aim 1...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $783,885 for Project Grant R01HL181589 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research on the role of NTRK2 isoforms in alveolar injury and repair related to bronchopulmonary dysplasia (BPD), a chronic lung disease affecting approximately 10,000 premature infants annually in the United States. The research employs multiomic profiling...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $770,000 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research unraveling endothelial-cardiomyocyte crosstalk in cardiomyopathy using an integrated multimodal approach. The research examines molecular mechanisms by which endothelial dysfunction contributes to cardiac dysfunction in cardiomyopathy, focusing on cell-to-cell signaling between endothelial cells...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $1.564 million on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of long noncoding RNAs and micropeptides in inflammation, lipid metabolism, and atherosclerosis. The project spans two research aims. Aim 1 examines a macrophage micropeptide named BRIK, testing its role in integrating metabolic and immune signaling and its contribution to...
- The National Heart, Lung, and Blood Institute awarded the University of California, Santa Barbara $130,955 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how viscoelastic properties and growth factor sequestering influence induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) using engineered biomaterials. The project examines the interplay between cardiac tissue viscoelasticity and growth factor signaling in both healthy and...
- The National Heart, Lung, and Blood Institute of the Department of Health and Human Services awarded the University of California, Los Angeles $3,134,805 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on alternative polyadenylation in cardiovascular disease. The recipient will integrate computational techniques with molecular, cellular, and animal model studies to elucidate how alternative polyadenylation (APA) contributes to cardiovascular...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $724,200 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial cell fate switches and dysfunction driven by fibrotic matrix remodeling. The research uses mouse models and an in vitro human microphysiological system of arteriole and venule-scale microvessels embedded within tunable stromal mimetic matrices to demonstrate how fibrotic physical cues...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $618,352 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanical regulation of endothelial lipid droplet metabolism and its role in vascular dysfunction. The research examines how oscillatory shear stress suppresses triglyceride hydrolysis by inactivating the transcription factor FOXO1, leading to lipid droplet accumulation in...
- The National Heart, Lung, and Blood Institute awarded the University of Arizona $778,582 on August 15, 2026, to identify genetic variants that perturb gene regulatory responses to athero-protective and athero-prone hemodynamic waveforms in human endothelial cells. The award funds research under the Cardiovascular Diseases Research program (CFDA 93.837). The project investigates how natural genetic variation governs endothelial cell responses to hemodynamic shear stress from blood flow, with...